July 27, 2017 / 11:45 AM / 2 years ago

BRIEF-Soligenix Inc initiates pivotal phase 3 clinical trial of SGX942

July 27 (Reuters) - Soligenix Inc:

* Soligenix initiates pivotal phase 3 clinical trial of sgx942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients

* Soligenix Inc - intend to begin with a controlled roll-out of U.S. Study sites, followed by addition of European centers in early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below